- Home
- CRMD vs VNDA Comparison
CRMD vs VNDA Comparison
Compare CRMD & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRMD | VNDA |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 509.9M | 474.0M |
| IPO Year | 2009 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CRMD | VNDA |
|---|---|---|
| Price | $7.22 | $7.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $15.20 | $14.90 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 780.00 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $311,709,000.00 | $216,105,000.00 |
| Revenue This Year | $0.30 | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | $3.51 | ★ N/A |
| Revenue Growth | ★ 617.03 | 8.72 |
| 52 Week Low | $6.13 | $3.81 |
| 52 Week High | $17.43 | $9.91 |
Technical Indicators
Market Signals| Indicator | CRMD | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 59.78 | 47.45 |
| Support Level | $6.14 | $7.12 |
| Resistance Level | $7.44 | $8.29 |
| Average True Range (ATR) | 0.24 | 0.45 |
| MACD | 0.12 | -0.03 |
| Stochastic Oscillator | 82.89 | 36.28 |
Price Performance
Historical ComparisonAbout CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.